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Drug resistance is a major issue in the treatment of glioblastoma. Almost all glioblastomas are intrinsically
resistant to chemotherapeutic temozolomide (TMZ) or develop resistance during treatment. The
interaction networks of microRNAs (miRNAs) and mRNAs likely regulate most biological processes and
can be employed to better understand complex processes including drug resistance in cancer. In this study,
we examined if integrative miRNA/mRNA network analysis using the web-service tool mirConnX could be
used to identify drug resistance factors in glioblastoma.We used TMZ-resistant glioblastoma cells and their
integrated miRNA/mRNA networks to identify TMZ-sensitizing factors. TMZ resistance was previously
induced in glioblastoma cell lines U87, Hs683, and LNZ308. miRNA/mRNA expression profiling of these
cells and integration of the profiles using mirConnX resulted in the identification of plant homeodomain
(PHD)-like finger 6 (PHF6) as a potential TMZ-sensitizing factor in resistant glioblastoma cells. Analysis of
PHF6 expression showed significant upregulation in glioblastoma as compared to normal tissue.
Interference with PHF6 expression in three TMZ-resistant subclones significantly enhanced TMZ-induced
cell kill in two of these cell lines. Altogether, these results demonstrate thatmirConnX is a feasible and useful
tool to investigate miRNA/mRNA interactions in TMZ-resistant cells and has potential to identify drug
resistance factors in glioblastoma.
G
lioblastoma is a significant problem in both adults and children. It is the most common primary brain
tumour in adults and despite the standard treatment, consisting of surgery, chemoradiation, and adjuv-
ant temozolomide (TMZ), the median survival for glioblastoma patients is only 14 months1,2. Drug
resistance is a major issue in the management of glioblastoma. DNA repair mechanisms hamper the cytotoxic
effect of the DNA damaging chemotherapeutic agent temozolomide in glioblastoma3–10. Canonical DNA repair
systems shown to be involved in TMZ resistance are the O6-methylguanine DNA methyltransferase (MGMT)
enzyme5–7 and the mismatch-repair (MMR) machinery3,4,8–10. Besides these DNA repair mechanisms, post-
transcriptional regulation of gene expression by microRNAs (miRNAs) has also been reported to play a role
in TMZ resistance11–22.
Most, if not all, biological processes are driven by the interactive networks of mRNAs and miRNAs23. Several
tools are currently available for integrative miRNA/mRNA regulatory network analysis, including mirConnX24,
MAGIA25, MMIA26, and GenMir1127. The algorithms of these programs combine sequence information with
gene expression data to create a condition-specific regulatory network. Such integratedmiRNA/mRNAnetworks
can be potentially related to aberrant cellular processes and specific diseases, including drug resistance and
cancer24,28,29.
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miRNAs are short non-coding single stranded molecules, consist-
ing of,22 nucleotides which regulate cellular processes by comple-
mentary binding to target messenger RNA (mRNA). Binding of the
miRNA with its ‘seed’ region to the 39 untranslated region (39UTR)
of the target mRNA results in translational inhibition of the
mRNA30–32. Importantly, multiple miRNAs can regulate the same
mRNA and single miRNAs can regulatemultiple mRNAs, indicating
a complex system of translational regulation30–32. Over the past dec-
ade multiple studies have demonstrated the importance of miRNAs
in cancer in general, and their involvement in TMZ resistance in
glioblastoma in particular11–22,31. miRNAs reported to influence
TMZ resistance in glioblastoma include miR-195, miR-455, miR-
1011, miR-181b12,18, miR-2113,16, miR-125b14, miR-14515, miR-21117,
miR-1719, miR-920, the miR-183/96/182 cluster21, and miR-221/
22222. However, so far no comprehensive network analysis has been
performed on integrated miRNA/mRNA expression profiles of drug
resistance in glioblastoma cells.
In this study, we examined whether mirConnX can be used to
identify drug resistance factors in glioblastoma. As proof of concept,
we employed three glioblastoma cell lines and their TMZ-resistant
subclones and performed comprehensive integrative analysis of their
mRNA/miRNA expression profiles in order to identify potential
TMZ-sensitizing factors. Integration of these profiles using
mirConnX resulted in the identification of plant homeodomain
(PHD)-like finger 6 (PHF6) as being a potential TMZ-sensitizing
factor. Altogether, these results demonstrate that mirConnX is a
feasible and useful tool to examine miRNA/mRNA interactions in
TMZ-resistant cells and is potentially useful for the identification of
new drug targets.
Results
RNA profiling of TMZ-sensitive glioblastoma cells and their
resistant subclones. TMZ resistance was induced in duplicate in
the glioblastoma cell lines Hs683, U87, and LNZ308, creating two
independent resistant subclones of each wild type cell line as
described previously33. TMZ IC50 values of the resistant subclones
were increased.2-fold compared to the wild type cells33. RNA from
both the wild type and the resistant cells was isolated and used for
mRNA microarray expression profiling as described previously33.
The same RNAwas also used to performmiRNAmicroarray expres-
sion analysis. miRNA expression profiles of Hs683, U87, and LNZ308
wild type and their resistant subclones are depicted in heatmap
format (Fig. 1a). The miRNAs listed were sorted based on overall
expression levels in all cell lines, both TMZ-sensitive and TMZ-
resistant, with highly expressed miRNAs at the top and lower
expressed miRNAs at the bottom. In order to quickly scan if
specific miRNAs were differentially expressed in the resistant
subclones compared to the wild type cell lines, we used the simple
ad hoc method fold change to calculate the resistant/wild type
expression ratio for each miRNA in each wild type and resistant
subclone pair separately. miRNAs with an expression ratio of $1.5
were considered upregulated andmiRNAs with an expression ratio of
#0.67 were considered downregulated. We identified differentially
expressed miRNAs in individual resistant subclones when comparing
them to their wild type counterparts. However, no common up- or
downregulated miRNAs were identified that were differentially
expressed in all resistant subclones (Fig. 1b). Since multiple
miRNAs can regulate the same mRNA in a complex regulatory
system of translational repression, we decided to use both mRNA
and miRNA expression profiles of the wild type and TMZ-resistant
cell lines for integrative network analysis using mirConnX to identify
potential drug targets that would likely be missed when considering
only mRNAs targeted by individual miRNAs.
Integrative miRNA/mRNA network analysis using mirConnX
identifies PHF6 as a potential target of multiple miRNAs in
TMZ-resistant glioblastoma cells. The input requirements for the
mirConnX web interface include at least six matched columns of
mRNA and miRNA expression data24. Furthermore, type of species
and statistical analysis method need to be specified. We used
Pearson’s correlation as an association measure of choice to exa-
mine correlations between miRNAs and mRNAs in our datasets,
generating a dynamic network of miRNA/mRNA interactions
extracted from the provided expression data. Subsequently, mir-
ConnX combined this dynamic network with a prior constructed
static network consisting of computationally-based miRNA target
predictions supplemented with interactions found in literature. mir-
ConnX used an integration function with user-specified weights to
combine these networks24.We analysed the expression profiles of the
wild type cells and the resistant cells separately. Integration of the
miRNA and mRNA expression profiles of the TMZ-sensitive or
TMZ-resistant subclones using mirConnX resulted in the regula-
tory networks as depicted in Fig. 2. The miRNAs are depicted as
blue squares and mRNAs as orange circles. The effect of the
interaction (inactivation or activation) is represented by arrows in
green (activation) and bar-headed lines in red (inactivation). Because
we were interested in the regulatory miRNA/mRNA processes
involved in TMZ resistance, we focussed on the interaction net-
work obtained from the expression profiles of the TMZ-resistant
subclones. We determined which mRNA depicted in the network
is potentially targeted by the largest set of either upregulated or
downregulated miRNAs in these cells. The plant homeodomain
(PHD)-like finger 6, PHF6 and OTU domain containing 4,
OTUD4 were potential targets of each of five miRNAs in the
network of the TMZ-resistant subclones (Fig. 3a). Importantly,
PHF6 and OTUD4 were not present in the interaction network
obtained from the miRNA/mRNA expression profiles of the wild
type TMZ-sensitive cell lines. Interestingly, both PHF6 and
OTUD4 were not identified in our previous mRNA expression
analysis of these cells33, and are thus good candidates to
demonstrate the added value of using integrative analysis of
miRNA and mRNA expression profiles. We continued our analysis
with PHF6, based on its predicted target interactions as shown in
Fig. 3b. miR-143, miR-93, miR-183, miR-96, and miR-214 show a
predicted repressive effect on PHF6, with the strength of the interac-
tions, based on a regulation score calculated bymirConnX24, between
the five miRNAs and the 39UTR of PHF6 close to 1 (p,0.05),
indicating strong interactions (range, 0–1). In Fig. 3c, we confirm
the alignment between the different miRNAs and the 39UTR region
of PHF6 in independent databases. miR-143, miR-93, miR-183, and
miR-214 show efficient base-pairing with PHF6. However, we were
not able to confirm PHF6 as a potential target of miR-96 in these
databases. Altogether, the mirConnX interaction network analysis
demonstrates a potential role for PHF6 in the integrative mRNA/
miRNA network of TMZ-resistant glioblastoma cells.
PHF6 expression is increased in TMZ-resistant cells and primary
glioblastoma samples. We determined the endogenous PHF6
mRNA expression levels in Hs683, U87, and LNZ308 wild type
cells and their TMZ-resistant subclones by qRT-PCR to further
evaluate the findings from the mirConnX integration network
(Fig. 4a). We observed a .4-fold increase in PHF6 expression in
both TMZ-resistant subclones of Hs683 and U87. PHF6 was even
.40-fold increased in the second subclone U87-R2 compared to the
wild type cells. No change on PHF6 mRNA expression level was
observed in the resistant subclones of LNZ308. In addition, using
themicroarray analysis and visualization platformR2 (http://r2.amc.
nl), we found that the PHF6 mRNA expression level is significantly
increased in glioblastoma tissue as well as in grade II and III
astrocytoma tissue compared to different regions of normal brain
tissue (p,0.01) (Fig. 4b)34–38. Since miRNAs function as post-
transcriptional regulators, the effect of these miRNAs on PHF6
www.nature.com/scientificreports
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Figure 1 | miRNA expression profiles of wild type and TMZ-resistant subclones. (a), overall miRNA expression profiles of Hs683, U87, and LNZ308
wild type and resistant subclones, sorted based on overall expression levels in all cell lines, both TMZ-sensitive and TMZ-resistant, with highly expressed
miRNAs at the top and lowly expressed miRNAs at the bottom. (b), heatmap of upregulated (left) and down regulated (right) miRNAs in resistant
subclones. TMZRES UP heatmap: blue5 strong upregulation, light blue5 upregulation, red5 modest upregulation. TMZRES DOWN heatmap: red5
strong downregulation, light red5 downregulation, blue5 modest downregulation.
www.nature.com/scientificreports
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mRNA translation is likely to be visible on the protein level.
Therefore, we performed Western blotting for PHF6 to determine
the protein expression levels in the wild type and resistant cell lines
(Fig. 4c). We observed amodest increase in PHF6 protein expression
in the TMZ-resistant subclones of U87 and LNZ308. However, we
did not reproducibly observe an increased PHF6 protein expression
in Hs683-R1 and -R2 cells, although we did measure an increase in
PHF6 mRNA expression in these subclones. These results indicate
that TMZ resistance in the glioblastoma subclones of U87 seems to
correlate with increased PHF6 mRNA and protein expression, in
subclones of Hs683 with increased PHF6 mRNA expression only,
and in subclones of LNZ308 with increased PHF6 protein expression
only, although the differences observed on protein level were at most
modest. Furthermore, PHF6 protein was high to moderately
expressed in three glioblastoma cell lines (Fig. 4d). Finally, we
evaluated PHF6 protein expression in high-grade glioma samples
and normal human brain tissues, using the Human Protein Atlas
(Fig. 4e, Table 1)39. Most glioma samples showed high to medium
PHF6 protein expression. Cell types in different normal brain regions
showed variable PHF6 expression (Table 1). Neuronal cells in the
cortex showed high PHF6 expression. Glial cells in the cortex showed
medium PHF6 expression while these cells showed low expression of
PHF6 in the hippocampus and lateral ventricle wall. In normal
cerebellum, PHF6 was found to be highly expressed.
PHF6 knockdown in combination with TMZ treatment decreases
cell viability. As proof of concept of potential drug target
confirmation, we performed functional analysis of PHF6 in TMZ
resistance by PHF6 knockdown in Hs683-R1, U87-R1, and
LNZ308-R1 cells using siRNAs in the presence or absence of TMZ.
Cells were transfected with siRNAs against PHF6 (siPHF6) or with a
non-targeting siRNA (siNT) as control. After transfection, we first
performed qRT-PCR on PHF6 to determine if the transfection was
successful (Fig. 5a). PHF6mRNA levels were significantly reduced in
U87-R1 and Hs683-R1 cells transfected with siPHF6 compared to
cells transfected with the control siRNA (p,0.05), however,
knockdown of PHF6 mRNA in Hs683-R1 was less pronounced
(,2-fold). Next, the effect of combined PHF6 knockdown and
TMZ treatment on cell viability was determined (Fig. 5b and c).
DAPI-stained nuclei were quantified, in order to determine cell
viability after treatment (Fig. 5b and c). Treatment with TMZ had
a minor effect on cell viability in the non-transfected cells.
Transfection with the control siRNA had no effect in U87-R1 cells
and aminor effect in LNZ308-R1 cells while transfection toxicity was
observed in Hs683-R1 cells. Transfection with siPHF6 resulted in a
significant reduction in the number of cells compared to cells
transfected with the control siRNA in U87-R1 and LNZ308-R1
cells (p,0.05). Addition of TMZ 24 hrs after transfection resulted
in enhanced cell kill as compared to TMZ or siPHF6 alone in U87-R1
Figure 2 | miRNA/mRNA interaction networks of wild type glioblastoma cells (left) and TMZ-resistant subclones (right), generated by mirConnX.
The miRNAs are depicted as blue squares, mRNAs as orange circles, and transcription factors (TFs) as green triangles. The effect of the interaction
(activation or inactivation) is represented by arrows in green (activation) and bar-headed lines in red (inactivation). Magnification of network of TMZ-
resistant cells is shown in boxed area.
www.nature.com/scientificreports
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and LNZ308-R1 cells (p,0.05) (Fig. 5c). In conclusion, these data
show that PHF6 knockdown was successful and in combination with
TMZ it resulted in a modest but significant effect on viability in two
of three TMZ-resistant glioblastoma cells tested.
Discussion
The aim of this study was to determine whether integrative miRNA/
mRNA network analysis is a feasible technique for the identification
of drug resistance factors in glioblastoma. We used TMZ-sensitive
glioblastoma cell lines and their TMZ-resistant subclones as a proof
of concept to identify potential TMZ-sensitizing factors. mirConnX
was used to generate integrative interaction networks of miRNA/
mRNA expression data of these TMZ-resistant and -sensitive glio-
blastoma cells, and allowed for the identification of PHF6 as a poten-
tial TMZ-sensitizing drug target in glioblastoma. This tool was used
before in a study performed by Kusko et al.29 in which it demon-
strated its applicability for the identification of miRNAs that co-vary
with differentially expressed p53/hypoxia genes in idiopathic pulmo-
nary fibrosis and emphysema.
A limitation of mirConnX is that separate interaction networks
have to be built in order to compare two different conditions, as
shown here for the wild type and TMZ-resistant conditions. This
Figure 3 | Integrative miRNA/mRNA network analysis using mirConnX identifies PHF6 as a target of multiple miRNAs in TMZ-resistant
glioblastoma cells. (a), mRNAs targeted by at least three miRNAs in the interaction network of TMZ-resistant subclones. (b), miRNAs miR-143, -93, -
183, -96, and -214 potentially target PHF6 mRNA in our TMZ-resistant subclones. Shown are the effect of the interaction (repression) between miRNA
and mRNA, the strength of the regulation (regulation score), and its respective p-value. The regulation score calculated by mirConnX is based on the
weight of the prior static network constructed by mirConnX and the weight of the association measure (Pearson’s correlation) extracted from the user-
supplied expression data24. (c), alignment between the different miRNAs and the 39UTR region of PHF6 in independent databases. miR-96 is not
identified as targeting PHF6 in these databases. miR-96 is encoded within ,10 kb of miR-183.
www.nature.com/scientificreports
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factor has been taken into account in the algorithm Classification
based Analysis of Paired Expression data of RNA (CAPE RNA),
developed by Hecker et al.40. This tool puts the emphasis on differ-
entially occurring interactions between different samples in a collect-
ive dataset but does not seem to have an integrated transcription
factor function as for mirConnX. Furthermore, Bar-Joseph et al.41
reported thatmiRNA andmRNA interaction networks can shift over
time suggesting that it is a dynamic process. Schulz et al.42 developed
Figure 4 | PHF6 mRNA and/or protein expression is increased in TMZ-resistant cells and primary glioblastoma samples. (a), PHF6 mRNA levels in
wild type and TMZ-resistant subclones as determined by qRT-PCR. (b), in silico analysis of PHF6 mRNA expression in normal brain tissue (grey) of
different brain regions (R15entorhinal cortex, R25hippocampus, R35post central gyrus, R45superior frontal gyrus)34, in glioblastoma (grade IV)
tissue, and in grade II (II) and III astrocytoma (III) tissue (dark grey)35–38 using R2 analysis software. (c), PHF6 protein expression in Hs683, U87, and
LNZ308 wild type and TMZ-resistant subclones as determined byWestern blotting. (d), immunofluorescent staining of PHF6 (green) in the nucleolus of
U251 glioblastoma cells.Microtubules are stained in red. PHF6 is highly expression inU251 andU138 glioblastoma cell lines andmoderately expressed in
U87 glioblastoma cell line. (e), PHF6 protein expression in normal brain tissue (cortex, hippocampus, lateral ventricle wall, and cerebellum) and in high-
grade glioma tissue (the Human Protein Atlas). These images were derived from the Human Protein Atlas. Shown are averages, error bars indicate SD.
*p,0.05 student’s t test.
www.nature.com/scientificreports
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the algorithm Development of MiRNA Dynamic Regulatory Events
Miner (mirDREM), a tool that allows reconstruction of dynamic
regulatory networks that model the effects of miRNAs and TFs on
their targets over time. It could be of value to determine the dynamics
of these interactions in the TMZ-sensitive and TMZ-resistant cells
used in this study, e.g. in the presence of TMZ.
Here, mirConnX identified PHF6 to be targeted by the largest set
of miRNAs, namely miR-143, miR-93, miR-183, miR-96, and miR-
214, in our TMZ-resistant subclones. In each individual TMZ-res-
istant cell line a different combination of these miRNAs seems to
control PHF6 regulation. This could be an explanation for the vari-
ation in PHF6 expression observed in the different resistant cell lines.
Using independent databases, we confirmed the strong binding
potential between miR-143, miR-93, miR-183, and miR-214 and
the 39UTR of PHF6. Of these miRNAs, only miR-96 was not iden-
tified by these prediction programs to strongly interact with PHF6,
which could be due to its close proximity to miR-183. The miRNA-
183/96/182 cluster has been previously implicated to play a role in
TMZ resistance. However, in that study21 overexpression of the clus-
ter resulted in TMZ resistance while our study suggests that the
interaction of miR-183 and miR-96 and PHF6 mRNA is involved
in induced TMZ resistance.
Further analysis of PHF6 expression in our TMZ-resistant and -
sensitive cells showed mRNA upregulation of PHF6 in the resistant
subclones of Hs683 and U87 but not in the resistant subclones of
LNZ308. On the protein level, both subclones of U87 and LNZ308
showed a modest increase of PHF6. As mentioned above, PHF6
expression is potentially regulated by a different combination of
miRNAs in each of the resistant cell lines and could explain the
variation in PHF6 expression. Functional analysis of PHF6 express-
ion in the context of TMZ resistance was performed using siRNAs
against PHF6 in combination with TMZ treatment. We observed a
modest effect on cell viability when we combined the siRNA against
PHF6 with TMZ in comparison to TMZ treatment or transfection
with PHF6 siRNA alone in U87-R1 and LNZ308-R1 cells. This effect
was not detected in the TMZ-resistant subcloneHs683-R1 in which a
relatively high transfection toxicity was observed. Furthermore,
Hs683-R1 showed no increase in PHF6 protein expression compared
to its wild type counterpart, which could be an additional explanation
for the lack of effect observed in these cells. In addition, knockdown
of PHF6 in Hs683-R1 cells is less pronounced compared to PHF6
knockdown inU87-R1 cells and could also add to the lack of effect on
cell viability observed in this cell line.
The PHF6 gene is reported to be involved in cell cycle control and
genomic maintenance43. It is a nucleolus, ribosomal RNA promoter-
associated protein that contains two PHD-like zinc finger domains.
PHF6 interacts with its PHD1 domain with upstream binding factor
(UBF)43. UBF specifically interacts with the ribosomal RNA (rRNA)
promoter region, thereby activating rRNA transcription. PHF6 is a
negative regulator of UBF and, therefore, suppresses rRNA tran-
scription43,44. It has also been reported that PHF6 interacts with
the nucleosome remodelling and deacetylation (NuRD) complex45.
The NuRD complex includes two histone deacetylases (HDAC1/2)
and possesses nucleosome remodelling activity. Thereby, the PHF6-
NuRD complex reveals a role for PHF6 in chromatin structure
modification45,46. Moreover, it has been shown that down regulation
or loss of function, by miRNAs or somatic mutations, of PHF6 con-
tributes to the development of T-cell acute lymphoblastic leukemia
(T-ALL) and acute myeloid leukemia (AML) suggesting that PHF6
functions as a tumour suppressor gene in these hematologic
malignancies43,47–49.
The mechanism through which PHF6 could result in TMZ resist-
ance in glioblastoma cells is not clear. It is possible that treatment
with TMZ results in a genotoxic stress response causing the induc-
tion of PHF6. As mentioned previously, PHF6 has been reported to
contribute to genomic maintenance and cell cycle control43. PHF6
inhibits rRNA synthesis, resulting in a decrease in ribosome biogen-
esis, which may ultimately lead to ribosomal stress. It has been
reported that upon ribosomal stress, the ribosomal proteins (RPs)
L5 and L11 are translocated from the nucleolus to the nucleo-
plasm50,51. In the nucleoplasm, L5 and/or L11 could inhibit
MDM2, a partner of p53, resulting in the induction of a p53 res-
ponse50. This response will force cells into senescence, apoptosis, or
cell cycle arrest52. However, thismechanismwould only be applicable
to cells that have a wild type p53, as is the case in U87 cells but not in
LNZ308 and Hs683 cells, which harbour mutant p53. Therefore, the
mechanism via which PHF6 could lead to TMZ resistance warrants
further investigation.
Previously, we identified TMZ resistance factors solely using the
mRNA expression profiles of these cells33. In that study, PHF6 was
not identified when only considering differences in mRNA express-
ion levels between TMZ-sensitive wild type cells and their TMZ-
resistant subclones. Since differential regulation of miRNA and
mRNA pairs plays an important role in multiple cellular processes,
including drug resistance in cancer, taking into account gene
expression regulation by miRNAs in drug resistance can add to the
understanding of TMZ resistance in glioblastoma. Therefore, this
study shows the added value of a systems biology approach using
software tools such as mirConnX to examine drug resistance in
glioblastoma. This approach may complement the studies exploring
for TMZ resistance factors in glioblastoma based on gene expression
only and can provide novel insights in mechanisms underlying TMZ
resistance. In addition, integration of miRNA and mRNA profiles to
examine drug resistance has been applied before in anti-estrogen-
resistance in breast cancer cells53. There, they showed the usefulness
of this approach in the identification of miRNA-related network
clusters that contribute to anti-estrogen resistance.
In conclusion, in this study we show, using a relatively small
sample size, that network analysis programs such as mirConnX
can be useful tools to examine miRNA/mRNA interactions in order
Table 1 | PHF6 protein expression in different cell types in different brain regions and in high-grade glioma cells as shown in Fig. 4d (the
Human Protein Atlas). Light grey is n.a. for these brain regions
Cerebral cortex Hippocampus Lateral ventricle wall Cerebellum High-grade glioma
Neuronal cells High Medium Low
Glial cells Medium Low Low
Endothelial cells Medium
Neuropil Not detected
Purkinje cells Medium
Cells in granular layer High
Cells in molecular layer High
Tumor cells High (5/12)
Medium (6/12)
Low (1/12)
www.nature.com/scientificreports
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to identify potential drug targets in glioblastoma. In addition, integ-
rative miRNA/mRNA network analysis using such software tools
may be considered for the identification of drug resistance factors
in other diseases as well.
Methods
Cells. Generation of TMZ-resistant glioblastoma subclones was described
previously33. Briefly, parental Hs683, U87, and LNZ308 glioblastoma cell lines were
treated twice a week in duplicate with 33 mM TMZ for multiple weeks until two
independent resistant subclones were generated. Hs683 (WT, R1 and R2), U87 (WT,
R1 and R2), and LNZ308 (WT, R1 and R2) cells were cultured inDulbecco’sModified
Eagle’s Medium (DMEM; PAA Laboratories, GmbH, Pasching, Austria))
supplemented with 10% fetal bovine serum (FBS) (PAA Laboratories, GmbH,
Pasching, Austria), and 1 mg/ml penicillin-streptomycin (both PAA Laboratories,
GmbH, Pasching, Austria) at 37uC and 5% CO2 in a humidified incubator.
mRNA and miRNA gene expression analysis. Total RNA was isolated using
mirVana miRNA isolation kit (Life Technologies). mRNA microarray expression
analysis was performed previously, as described elsewhere33, using Agilent 4344K
Whole Human GE arrays (Agilent Technologies), according to the manufacturer’s
instructions. The same RNA samples were used for miRNA profiling. Samples were
hybridized to Agilent SurePrint G3 Human v16 miRNA 8360k arrays (Agilent
Figure 5 | PHF6 knockdown in combination with TMZ treatment decreases cell viability. (a), PHF6 mRNA expression in U87-R1 and Hs683-R1 cells
24 hrs after transfection with siPHF6 or siNT as determined by qRT-PCR. (b), representative images of the different treatment conditions (CTRL,
TMZ, siNT/CTRL, siNT/TMZ, siPHF6/CTRL, siPHF6/TMZ) in Hs683-R1, U87-R1, and LNZ308-R1 cells four days after treatment with TMZ. The
panels show DAPI-stained nuclei. Size bar, 20 mm. (c), quantification of cell viability of Hs683-R1, U87-R1, and LNZ308-R1 cells after treatment with
siPHF6 or siNT in the presence or absence of 50 mM (Hs683-R1), 300 mM (U87-R1) or 400 mM (LNZ308-R1) TMZ. Shown are averages, error bars
indicate SD. *p,0.05 student’s t test. * in c indicates statistical significance of combination of PHF6 knockdown and TMZ compared to PHF6
knockdown or TMZ treatment alone.
www.nature.com/scientificreports
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Technologies). Scanning of the slides was performedwithAgilentMicroarray scanner
(G2565BA). Image analysis was performed using feature extraction software version
10.5 (Agilent Technologies, Inc., CA, USA). The Agilent miRNA_105_Dec08_
protocol was applied using default settings. For each wild type and resistant subclone,
a normalization factor was calculated by dividing the sum of all intensities of theWT
by the sum of all intensities of theWT and the resistant subclones. Subsequently, each
intensity value was multiplied by its corresponding normalization factor. Intensity
values,2-fold of background intensity level were regarded as not detectable. Relative
miRNA expression in R1 or R2 cells compared to WT cells was determined by
calculating the resistant/wild type expression ratio. A miRNA with an expression
ratio of$1.5 was considered upregulated while a miRNA with an expression ratio of
#0.67 was considered downregulated.
mirConnX. The web interface mirConnX (http://www.benoslab.pitt.edu/mirconnx)
was used to generatemRNA/miRNA interaction networks of thewild type cells and of
the resistant subclones24. The normalized miRNA and mRNAmicroarray expression
data each containing six matched columns representing different samples were used
as input files for the mirConnX software. Next, we specified the parameters of choice.
We selected human_h19_(GRCh37)_20111109 for organism type. Gene symbol and
ID were selected for gene ID and miRNA ID, respectively. In the analysis options
section, we selected Pearson’s correlation as the association measure of choice. The
regulation threshold for theminimum integrated regulation score was set at 0.95. The
regulation score is calculated using the weighted sum of both the user-specified
weight of the prior static network and the weight of the association measure, in this
case Pearson’s correlation, which determined correlations between miRNA and
mRNA interactions in user-provided expression data24. We selected the option to
calculate the presence of feed-forward loops. For the prior weight factor we selected
0.3. To further analyze the specific miRNA/mRNA interactions, we downloaded the
data from the network as spreadsheets.We compared themiRNA/mRNA interaction
lists of the TMZ-sensitive and the TMZ-resistant network manually to determine
which mRNA depicted in the TMZ-resistant network is potentially targeted by the
largest set of either upregulated or downregulated miRNAs and is absent in the TMZ-
sensitive network.
In silico analysis of PHF6 mRNA and protein expression. For assessing PHF6
mRNA expression in glioblastoma and different regions of normal brain tissue, we
used R2, the microarray analysis and visualization tool provided by the Department
of Human Genetics of the Academic Medical Centre, Amsterdam, The Netherlands
(http://r2.amc.nl). MAS5.0 normalized microarray datasets of glioblastoma35–38 were
compared to different regions of normal brain34.
The Human Protein Atlas was used to check for protein expression levels of PHF6
in high-grade glioma tissue and different regions of normal brain tissue39.
qRT-PCR. Total RNA was isolated using TRIzol RNA isolation protocol (Life
Technologies, CA, USA), according to the manufacturer’s protocol. RNA
concentrations were determined using the NanoDrop 1000 (Thermo Scientific, MA,
USA) and, subsequently, equal amounts of RNA were converted into cDNA using
Omniscript kit (Qiagen, Valencia, CA, USA). QuantiTect Primer Assay (Qiagen,
Valencia, CA, USA) including forward and reverse primers for PHF6 were used to
measure PHF6 mRNA levels. Forward and reverse primers (Biolegio, Nijmegen, The
Netherlands) for GAPDH were used for GAPDH mRNA detection. Next, qRT-PCR
was performed using the 7500 real-time PCR system (Applied Biosystems, Life
Technologies, CA, USA). The data were normalized to GAPDH expression levels.
TheCt values were used to calculate the relative fold difference inmRNA levels (DDCt
method).
Western blot. Expression levels of PHF6 were assessed by Western blot analysis.
After cell lysis, 40 mg of protein was loaded on gel and was transferred to a
polyvinylidene difluoride (PVDF) membrane after electrophoresis. Next, the
membranes were incubated with the primary antibodies rabbit anti-PHF6 (151,000;
Sigma-Aldrich, Missouri, USA) and mouse anti-b-actin (1510,000; Santa Cruz
Biotechnology, Texas, USA) over night (O/N) at 4uC. Subsequently, the membranes
were incubated with green goat-anti-rabbit and red goat-anti-mouse IR dye-labeled
secondary antibodies (1510,000; IRDye LI-COR Biosciences, Nebraska, USA) for
2 hours at room temperature. Protein detection and visualization of PHF6 and b-
actin proteins were performed with Odyssey Infrared Imaging System (LI-CORH
Biosciences, Nebraska, USA). Analysis and quantification of protein expression were
performed with Image Studio (LI-CORH Biosciences, Nebraska, USA) and ImageJ.
PHF6 protein expression was normalized to b-actin protein expression levels.
Cell viability assay. Cells were plated in 96-well plates and transfected after 24 hrs
with 66 nM of siPHF6 (Qiagen) or siNT (Thermo Scientific Dharmacon) using
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The next day, cells were treated
with TMZ and incubated for another 72 hrs. Cells were then washed with PBS and
fixed in 3.6% formaldehyde. Permeabilization of the cell membrane was performed
with PBS containing 0.1% Trition X-100. Next, we used 49,6-diamidino-2-
phenylindole (DAPI; 0.3 mg/ml in PBS) to stain the nuclei of the cells. Cell number
was assessed by counting the number of DAPI-stained cells using the Acumen Ex3
laser scanning cytometer (TTP LabTech, Royston, UK).
Statistical analysis. Differences in biological properties between treated and
untreated cells were analysed using two-sided Student’s t-test. Differences between
groups were determined using one-way ANOVA. The p values ,0.05 were
considered statistically significant. Data were analyzed usingGraphPadPrism version
5 software (GraphPad Software, La Jolla, CA, USA).
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